Skip to main content
. 2021 Aug 11;7(33):eabg5995. doi: 10.1126/sciadv.abg5995

Table 1. Cell therapy–based clinical trials for COVID-19.

Search approach: performed 1 January 2021; Clinicaltrials.gov: advanced search; Condition - –OVID; Study Type -Interventi–nal; Intervention/treatment - Cell; of 157 studies, exclude– non–COVID-19 patients (n = 12) and non–cell therapy trials (n = 56); leaving 89 available studies. NCT, national clinical trial.

Cell type Title Status Phase Country NCT number
Mesenchymal
stem cells
Clinical trial of
allogeneic
mesenchymal cells
from umbilical cord
tissue in patients
with COVID-19		 Recruiting Phase 2 Spain NCT04366271
Autologous adipose-
derived stem cells
(AdMSCs) for
COVID-19		 Not yet recruiting Phase 2 United States NCT04428801
Treatment of severe
COVID-19
pneumonia with
allogeneic
mesenchymal
stromal cells
(COVID_MSV)		 Recruiting Phase 2 Spain NCT04361942
Mesenchymal stem cell
infusion for
COVID-19 infection		 Recruiting Phase 2 Pakistan NCT04444271
Mesenchymal stem cell
for acute respiratory
distress syndrome
due for COVID-19		 Recruiting Phase 2 Mexico NCT04416139
Safety and feasibility of
allogenic MSC in the
treatment of
COVID-19		 Not yet recruiting Phase 1 Brazil NCT04467047
BAttLe against
COVID-19 using
mesenchYmal
stromal cells		 Not yet recruiting Phase 2 Spain NCT04348461
Mesenchymal stromal
cells for the
treatment of
SARS-CoV-2 induced
acute respiratory
failure (COVID-19
disease)		 Not yet recruiting Early phase 1 United States NCT04345601
Cellular immuno-
therapy for COVID-19
acute respiratory
distress syndrome -
Vanguard		 Recruiting Phase 1 Canada NCT04400032
Cord blood-derived
mesenchymal stem
cells for the
treatment of
COVID-19 related
acute respiratory
distress syndrome		 Recruiting Phase 1 United States NCT04565665
Safety and efficacy
study of allogeneic
human dental pulp
mesenchymal stem
cells to treat severe
COVID-19 patients		 Recruiting Phase 1|phase 2 China NCT04336254
Study of intravenous
administration of
allogeneic adipose
stem cells for
COVID-19		 Not yet recruiting Phase 1 United States NCT04486001
Safety and efficacy of
mesenchymal stem
cells in the
management of
severe COVID-19
pneumonia		 Not yet recruiting Phase 2 Colombia NCT04429763
NestaCell mesenchymal
stem cell to treat
patients with severe
COVID-19
pneumonia		 Not yet recruiting Phase 2 Brazil NCT04315987
Use of mesenchymal
stem cells in acute
respiratory distress
syndrome caused by
COVID-19		 Active, not recruiting Early phase 1 Mexico NCT04456361
Efficacy of infusions of
MSC from Wharton
jelly in the
SARS-Cov-2
(COVID-19) related
acute respiratory
distress syndrome		 Not yet recruiting Phase 2 France NCT04625738
hCT-MSCs for COVID19
ARDS		 Recruiting Phase 1|phase 2 United States NCT04399889
Clinical trial to assess
the efficacy of MSC
in patients with
ARDS due to
COVID-19		 Recruiting Phase 2 Spain NCT04615429
Treatment of Covid-19
associated
pneumonia with
allogenic pooled
olfactory mucosa-
derived
mesenchymal stem
cells		 Enrolling by invitation Phase 1|phase 2 Belarus NCT04382547
Clinical trial to assess
the safety and
efficacy of
intravenous
administration of
allogeneic adult
mesenchymal stem
cells of expanded
adipose tissue in
patients with severe
pneumonia due to
COVID-19		 Active, not recruiting Phase 1|phase 2 Spain NCT04366323
Regenerative medicine
for COVID-19 and
flu-elicited ARDS
using longeveron
mesenchymal stem
cells (LMSCs)
(RECOVER)		 Recruiting Phase 1 United States NCT04629105
An exploratory study of
ADR-001 in patients
with severe
pneumonia caused
by SARS-CoV-2
infection		 Not yet recruiting Phase 1 Japan NCT04522986
Novel coronavirus
induced severe
pneumonia treated
by dental pulp
mesenchymal stem
cells		 Not yet recruiting Early phase 1 China NCT04302519
Multiple dosing of
mesenchymal
stromal cells in
patients with ARDS
(COVID-19)		 Recruiting Phase 2 United States NCT04466098
MSC-based therapy in
COVID-19-associated
acute respiratory
distress syndrome		 Recruiting Phase 1 Brazil NCT04525378
Adipose mesenchymal
cells for abatement
of SARS-CoV-2
respiratory
compromise in
COVID-19 disease		 Not yet recruiting Phase 1 United States NCT04352803
Safety and efficacy of
intravenous
Wharton’s jelly
derived
mesenchymal stem
cells in acute
respiratory distress
syndrome due to
COVID 19		 Not yet recruiting Phase 1|phase 2 Colombia NCT04390152
Efficacy of intravenous
infusions of stem
cells in the treatment
of COVID-19 patients		 Recruiting Phase 2 Pakistan NCT04437823
Treatment with human
umbilical cord-
derived
mesenchymal stem
cells for severe
corona virus disease
2019 (COVID-19)		 Completed Phase 2 China NCT04288102
Therapeutic study to
evaluate the safety
and efficacy of
DW-MSC in
COVID-19 patients		 Active, not recruiting Phase 1 Indonesia NCT04535856
Administration of
allogenic UC-MSCs
as adjuvant therapy
for critically-ill
COVID-19 patients		 Recruiting Phase 1 Indonesia NCT04457609
Clinical research of
human
mesenchymal stem
cells in the treatment
of COVID-19
pneumonia		 Recruiting Phase 1|phase 2 China NCT04339660
Treatment of COVID-19
patients using
Wharton’s
jelly-mesenchymal
stem cells		 Recruiting Phase 1 Jordan NCT04313322
Study of human
umbilical cord
mesenchymal stem
cells in the treatment
of severe COVID-19		 Not yet recruiting Not applicable China NCT04273646
Mesenchymal stromal
cell therapy for
severe Covid-19
infection		 Recruiting Phase 1|phase 2 Belgium NCT04445454
Bone marrow-derived
mesenchymal stem
cell treatment for
severe patients with
coronavirus disease
2019 (COVID-19)		 Not yet recruiting Phase 1|phase 2 China NCT04346368
A study of cell therapy
in COVID-19 subjects
with acute kidney
injury who are
receiving renal
replacement therapy		 Recruiting Phase 1|phase 2 United States NCT04445220
Mesenchymal stem
cells in patients
diagnosed with
COVID-19		 Recruiting Phase 1 Mexico NCT04611256
Use of UC-MSCs for
COVID-19 patients		 Completed Phase 1|phase 2 United States NCT04355728
Mesenchymal stem cell
treatment for
pneumonia patients
infected with
COVID-19		 Recruiting Phase 1 China NCT04252118
Study to evaluate the
efficacy and safety of
AstroStem-V in
treatment of
COVID-19
pneumonia		 Not yet recruiting Phase 1|phase 2 South Korea NCT04527224
A randomized,
double-blind,
placebo-controlled
clinical trial to
determine the safety
and efficacy of Hope
Biosciences
allogeneic
mesenchymal stem
cell therapy
(HB-adMSCs) to
provide protection
against COVID-19		 Enrolling by invitation Phase 2 United States NCT04348435
A clinical trial to
determine the safety
and efficacy of Hope
Biosciences
autologous
mesenchymal stem
cell therapy
(HB-adMSCs) to
provide protection
against COVID-19		 Active, not recruiting Phase 2 United States NCT04349631
ASC therapy for
patients with severe
respiratory COVID-19		 Withdrawn Phase 1|phase 2 Denmark NCT04341610
Safety and effectiveness
of mesenchymal
stem cells in the
treatment of
pneumonia of
coronavirus disease
2019		 Active, not recruiting Early phase 1 China NCT04371601
Cell therapy using
umbilical cord-
derived
mesenchymal
stromal cells in
SARS-CoV-2-related
ARDS		 Active, not recruiting Phase 1|phase 2 France NCT04333368
Clinical use of stem
cells for the
treatment of
Covid-19		 Recruiting Phase 1|phase 2 Turkey NCT04392778
Mesenchymal stem
cells for the
treatment of
COVID-19		 Completed Phase 1 United States NCT04573270
Treatment of
coronavirus
COVID-19
pneumonia
(pathogen
SARS-CoV-2) with
cryopreserved
allogeneic P_MMSCs
and UC-MMSCs		 Recruiting Phase 1|phase 2 Ukraine NCT04461925
Efficacy and safety
Study of allogeneic
HB-adMSCs for the
treatment of
COVID-19		 Active, not recruiting Phase 2 United States NCT04362189
Use of hUC-MSC
product (BX-U001)
for the treatment of
COVID-19 With ARDS		 Not yet recruiting Phase 1|phase 2 United States NCT04452097
Mesenchymal stem
cells (MSCs) in
inflammation-
resolution programs
of coronavirus
disease 2019
(COVID-19) induced
acute respiratory
distress syndrome
(ARDS)		 Not yet recruiting Phase 2 Germany NCT04377334
Umbilical cord tissue
(UC) derived
mesenchymal stem
cells (MSCs) versus
placebo to treat
acute pulmonary
inflammation due to
COVID-19		 Not yet recruiting Phase 1 United States NCT04490486
Repair of acute
respiratory distress
syndrome by stromal
cell administration
(REALIST) (COVID-19)		 Recruiting Phase 1|phase 2 United Kingdom NCT03042143
The MEseNchymal
coviD-19 trial: A pilot
study to investigate
early efficacy of
MSCs in adults with
COVID-19		 Recruiting Phase 1|phase 2 Australia NCT04537351
Efficacy and safety
evaluation of
mesenchymal stem
cells for the
treatment of patients
with respiratory
distress due to
COVID-19		 Recruiting Phase 1|phase 2 Spain NCT04390139
Study of the safety of
therapeutic Tx with
immunomodulatory
MSC in adults with
COVID-19 infection
requiring mechanical
ventilation		 Recruiting Phase 1 United States NCT04397796
Open-label multicenter
study to evaluate the
efficacy of PLX-PAD
for the treatment of
COVID-19		 Recruiting Phase 2 Germany NCT04614025
MSCs in COVID-19
ARDS		 Active, not recruiting Phase 3 United States NCT04371393
Therapy for pneumonia
patients iInfected by
2019 novel
coronavirus		 Withdrawn Not applicable China NCT04293692
Umbilical cord(UC)-
derived
mesenchymal stem
cells (MSCs)
treatment for the
2019-novel
coronavirus (nCOV)
pneumonia		 Recruiting Phase 2 China NCT04269525
ACT-20 in patients with
severe COVID-19
pneumonia		 Not yet recruiting Phase 1|phase 2 United States NCT04398303
Double-blind,
multicenter, study to
evaluate the efficacy
of PLX PAD for the
treatment of
COVID-19		 Recruiting Phase 2 United States NCT04389450
Natural killer (NK) cells
Fase I clinical trial on NK
cells for COVID-19		 Not yet recruiting Phase 1 Brazil NCT04634370
A phase I/II study of
universal off-the-
shelf NKG2D-ACE2
CAR-NK Cells for
therapy of COVID-19		 Recruiting Phase 1|phase 2 China NCT04324996
Phase I / II clinical study
of immunotherapy
based on adoptive
cell transfer as a
therapeutic
alternative for
patients with
COVID-19 in
Colombia		 Not yet recruiting Phase 1|phase 2 Colombia NCT04344548
NK cells treatment for
COVID-19		 Recruiting Phase 1 China NCT04280224
Natural killer cell
(CYNK-001) infusions
in adults with
COVID-19		 Recruiting Phase 1|phase 2 United States NCT04365101
Study of FT516 for the
treatment of
COVID-19 in
hospitalized patients
with hypoxia		 Recruiting Phase 1 United States NCT04363346
An experiment to
evaluate the safety
of agenT-797 in
COVID-19 patients
with severe difficulty
breathing		 Recruiting Phase 1 United States NCT04582201
T cells
Part two of novel
adoptive cellular
therapy with
SARS-CoV-2 specific
T cells in patients
with severe
COVID-19		 Recruiting Phase 1|phase 2 Singapore NCT04457726
RAPA-501-Allo
off-the-shelf therapy
of COVID-19		 Recruiting Phase 1|phase 2 United States NCT04482699
REgulatory T cell
infuSion fOr lung
injury due to
COVID-19
PnEumonia		 Recruiting Phase 1 United States NCT04468971
Anti-SARS Cov-2 T cell
infusions for COVID 19		 Recruiting Phase 1 United States NCT04401410
Viral specific T-cells for
treatment of
COVID-19		 Not yet recruiting Phase 2 United States NCT04406064
Early apoptotic cells
Study evaluating safety,
tolerability and
efficacy of
Allocetra-OTS in
patients with
COVID-19		 Not yet recruiting Phase 1 Israel NCT04659304
Allocetra-OTS in
COVID-19		 Active, not recruiting Phase 1 Israel NCT04513470
Allocetra-OTS in
COVID-19, phase II		 Recruiting Phase 2 Israel NCT04590053
Other
Cardiosphere-derived
cells		 Intravenous infusion of
CAP-1002 in patients
with COVID-19		 Recruiting Phase 2 United States NCT04623671
CD34+ cells CLBS119 for repair of
COVID-19 induced
pulmonary damage		 Withdrawn Phase 1 United States NCT04522817
Cellular stromal vascular
fraction (cSVF)		 Use of cSVF Via IV
deployment for
residual lung
damage after
symptomatic
COVID-19 infection		 Recruiting Early phase 1 United States NCT04326036
Cord blood stem cells Stem cell educator
therapy treat the
viral inflammation in
COVID-19		 Not yet recruiting Phase 2 China NCT04299152
Decidual stromal cells Study of decidual
stromal cells to treat
COVID-19 respiratory
failure		 Not yet recruiting Not applicable Canada NCT04451291
Immunity- and
matrix-regulatory cells		 Safety and efficacy of
CAStem for severe
COVID-19 associated
with/without ARDS		 Recruiting Phase 1|phase 2 China NCT04331613
Multipotent adult
progenitor cells		 MultiStem
administration for
COVID-19 induced
ARDS (MACoVIA)		 Recruiting Phase 2|phase 3 United States NCT04367077
Peripheral blood
stem cells		 Study evaluating the
safety and efficacy of
autologous
non-hematopoietic
peripheral blood
stem cells in
COVID-19		 Completed Phase 1|phase 2 United Arab Emirates NCT04473170
Platelet-rich plasma and
cord blood		 Using PRP and cord
blood in treatment
of Covid -19		 Recruiting Not applicable Egypt NCT04393415
T and NK cells Safety infusion of
NatuRal KillEr celLs
or MEmory T cells as
adoptive therapy in
COVID-19
pnEumonia or
lymphopenia		 Recruiting Phase 1|phase 2 Spain NCT04578210
Umbilical cord lining
stem cells (ULSCs)		 Umbilical cord lining
stem cells (ULSC) in
patients with
COVID-19 ARDS		 Recruiting Phase 1|phase 2 United States NCT04494386